SARS-CoV-2 serology in HIV PrEP users during the COVID-19 pandemic.

Recruiting

• Conditions: HIV-PrEPSTD; Z29.21

• Registration Number: DRKS00022403
• Lead Sponsor: Klinikum Rechts der Isar

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2020-07-15
• Results First Posted: 2023-07-17
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 300

Inclusion Criteria

MSM reporting PrEP-use within last 90 months prior to screening visit
- Written informed consent.
- Age =18 years.

Exclusion Criteria

Persons with any kind of dependency on the investigator.

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Seroconversion rate pointprevalence of SARS-CoV-2 antibody during the time of this study.

Secondary Outcome Measures

Name	Time	Method
- Pointprevalence of SARS-CoV-2 antibodies at baseline.<br>- Pointprevalence of SARS-CoV-2 antibodies at follow-up visits.<br>- correlation of the seroprevalence and/or seroconversion of SARS-CoV-2 positivity with sexual behaviour and other sexual transmitted diseases (STDs), such as syphilis, N. gonococcae, M. genitalium, C.trachomatis or HIV.<br>